Table 1.

Current status of known TAK1 inhibitors

TAK1 inhibitor	Current status	Reference
siRNA	Commercially available from Dharmacon, Santa Cruz Biotechology and CST for research purposes	[7, 14, 33, 59]
5Z-7- oxozeaenol	Commercially available for research purposes	[60, 61]
LYTAK1	Not in clinical trials or in oncology and autoimmune studies. Patent information unknown	[62, 63] (see Acknowledgements)
ABC-FP	Patented by OSI Pharmaceuticals. Patent US8378104	[65]

ABC-FP: trans-4-{4-[7-amino-2-(1,2,3-benzothiadiazol-7-yl)-3-chlorofuro[2,3-c]pyridin-4-yl]-1H-pyrazol-1-yl}cyclohexanol; LYTAK: TAK1 inhibitor from Eli Lilly Pharmaceuticals; siRNA: small interfering RNA; TAK1: transforming growth factor β activated kinase 1.